XML 27 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue:    
Total revenue $ 67,783 $ 36,703
Operating expenses:    
Research and development 9,166 5,336
Selling and marketing 23,754 16,296
General and administrative 20,912 46,282
Intangible asset amortization 5,486 1,801
Total operating expenses 83,031 82,118
Loss from operations (15,248) (45,415)
Other income (loss), net 784 (248)
Loss before income taxes (14,464) (45,663)
Income tax benefit (3) (3,795)
Net loss $ (14,461) $ (41,868)
Net loss per common share, basic (in USD per share) $ (0.20) $ (0.66)
Net loss per common share, diluted (in USD per share) $ (0.20) $ (0.66)
Shares used to compute net loss per common share, basic (in shares) 71,229,672 63,331,702
Shares used to compute net loss per common share, diluted (in shares) 71,229,672 63,331,702
Testing revenue    
Revenue:    
Total revenue $ 55,980 $ 33,078
Operating expenses:    
Cost of revenue 17,523 10,832
Product revenue    
Revenue:    
Total revenue 2,979 3,059
Operating expenses:    
Cost of revenue 1,575 1,490
Biopharmaceutical and other revenue    
Revenue:    
Total revenue 8,824 566
Operating expenses:    
Cost of revenue $ 4,615 $ 81